Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019

Muktar Abadiga*, Tahir Hasen, Getu Mosisa, Eba Abdisa
School of Nursing and midwifery, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia

* muktarabadiga@gmail.com

Abstract

Background
Antiretroviral therapy has a remarkable clinical effect in reducing the progress of Acquired Immune Deficiency Syndrome. The clinical outcome of Anti-Retroviral therapy depends on strict adherence. Poor adherence reduces the effectiveness of antiretroviral therapy and increases viral replication. With changes in service delivery over time and differences in socio-demographic status from region to region, it is essential to measure adherence. Therefore, this study aimed to assess adherence to antiretroviral therapy and its associated factors among HIV/AIDS patients accessing treatment at Nekemte referral hospital, West Ethiopia.

Methods
Institutional based cross-sectional study was conducted on 311 HIV/AIDS patients from March 01 to March 30, 2019. The study participants were selected by a simple random sampling method and interviewed using structured questionnaires. Bivariable logistic regression was conducted to find an association between each independent variable and adherence to antiretroviral medication. Multivariable logistic regression was used to find the independent variables which best predict adherence. The statistical significance was measured using odds ratio at a 95% confidence interval with a p-value of less than 0.05.

Results
Out of a total of 311 patients sampled, 305 were participated in the study, making a response rate of 98.07%. From these 305 study participants, 73.1% (95% CI = 68.2, 78.0) were adherent to their medication. Having knowledge about HIV and its treatment (AOR = 8.24, 95% CI: 3.10, 21.92), having strong family/social support (AOR = 6.21, 95% CI: 1.39, 27.62), absence of adverse drug reaction (AOR = 5.33, 95% CI: 1.95, 14.57), absence of comorbidity of other chronic diseases (AOR = 5.72, 95% CI: 1.91, 17.16) and disclosing HIV
status to the family (AOR = 5.08, 95% CI: 2.09, 12.34) were significantly associated with an increased likelihood of adherence to antiretroviral medication.

Conclusion

The level of adherence to antiretroviral therapy was found low compared to WHO recommendation. The clinician should emphasize reducing adverse drug reaction, detecting and treating co-morbidities early, improving knowledge through health education, and encouraging the patients to disclose their HIV status to their families.

Background

Human immune deficiency virus (HIV) is one of the most destructive epidemics that continue to be a major global public health issue [1]. Globally, 36.7 million people were living with HIV/AIDS at the end of 2015 with approximately 70% residing in Sub-Saharan Africa [2]. In Ethiopia, the Federal HIV/AIDS Prevention and Control Office (EFHAPCO) indicates that there are over 718,550 peoples living with HIV/AIDS [3].

Ending HIV/AIDS as a public health threat includes achieving the 90-90-90 target set by WHO to ensure successful lifesaving treatment for millions of people [4]. The aim of 90–90–90 targets is to diagnose 90% of all HIV-positive persons, provide antiretroviral therapy for 90% of those diagnosed, and achieve viral suppression for 90% of those treated by 2020 [5]. This is estimated to result in 73% of people with HIV achieving full viral suppression [6].

Antiretroviral therapy is a lifelong activity to treat human immunodeficiency virus infection [1]. Adherence to medication reflects the extent to which a person’s behavior in taking medication corresponds with the recommendation from a health care provider [7]. ART decreases the burden of HIV on patients and prevents the occurrence of opportunistic infections [8 & 9]. The availability of ART has improved the survival rates of HIV patients and reduced HIV related comorbidities [10]. However, strict adherence to antiretroviral therapy is important to decrease the multiplication of the virus [11 & 12]. Different literature showed that above 95% adherence to the therapeutic regimen is required for HIV infected patients to reach full viral suppression [13–16].

The level of adherence to antiretroviral therapy vary from country to country and region to region. The level of adherence to ART is 85.5% in China [17], 84.0% in Myanmar [18], 71.0% in Northern Tanzania [19] and 62.2% in Ghana [20]. In Ethiopia, the rate of adherence to antiretroviral therapy is 88.2% [21]. Poor adherence to antiretroviral therapy reduces the effectiveness of ART and increases drug resistance [22 & 23]. Poor adherence to antiretroviral therapy is also linked to a decrease in CD4 count and higher mortality rates [24]. The studies have shown that factors such as socio-demographic and socio-cultural factors, side effects of ARVs, ART regimes, duration on ART, stress, depression, and anxiety were associated with ART adherence [25 & 26].

Adherence is a dynamic process that changes over time and there has been considerable progress of access to ART and HIV counseling, provision of free ART services, expansion of treatment and increased awareness over the past years. The magnitude and determinants of adherence differ across geopolitical zones with their unique characteristics of culture, economic status, religion, educational status, and health-seeking behaviors. Therefore, with the changes in service delivery and variation in socioeconomic status, it is essential to measure adherence from time to time and in different geographical settings. Since the Nekemte referral
hospital is providing services to more than 3 million peoples and over two thousand ART users, determining the level of ART adherence and identifying its determinants is essential for making appropriate interventions. Therefore, this study was aimed to assess the level of adherence to ART and its associated factors among HIV infected patients accessing treatment at Nekemte referral hospital, western Ethiopia.

**Methods**

**Study design and setting**

Institutional based cross-sectional study was conducted on HIV/AIDS patients accessing treatment at Nekemte referral hospital from March 01 to March 30, 2019. Nekemte referral hospital is one of the largest hospitals found in the western part of Ethiopia at a distance of 325 kilometers from the capital city Addis Ababa. There were 2251 HIV/AIDS patients on treatment follow up at Nekemte referral hospital at the time of the study. There were 21 medical doctors, 57 nurses, 42 midwives and 13 pharmacists working in this hospital. All ART patients on-treatment follow up at Nekemte referral hospital were the source population. All ART patients who had treatment follow up during the study period were the study population. All patients whose ages are 18 years and above were included in this study.

**Sample size determination and sampling techniques**

The sample size was calculated using the formula for estimation of a single population proportion ($n = \frac{(Z_{\alpha/2})^2 \times P (1-P)}{d^2}$) with the assumptions of 95% Confidence Level (CL) and marginal error ($d$) of 0.05. An adherence level of 0.74 (74.0%) was taken from the study conducted in Addis Ababa [27]. Based on this formula, the calculated sample size yields 296 study participants. After adding a non-response rate of 5% which is 15 study participants, a total of 311 ART patients were enrolled in the study. A simple random sampling using the lottery method was used to select the study participants. The sampling was done using a sampling framework or patient files. First, all 2251 patient cards were collected from the ART clinic and coded. Then, 311 patient cards were randomly selected using lottery methods. Finally, data were collected from randomly selected patients as they came for a hospital visit.

**Measurement and data collection procedure**

Data was collected using a structured questionnaire and a face-to-face interview was used for this study. In addition to the interview, other patient information was obtained from patient cards. The dependent variable was adherence to ART and the independent variables were socio-demographic, psychosocial and medication-related characteristics. Oslo 3-item social support scale was used to measure family/social support [28]. The 12 items short version of the HIV stigma scale was used to assess social stigma [29]. The adherence level was measured by counting the number of pills that remain in the patients’ bottles when he/she comes for follow up. Then, based on WHO guidelines, patients who reported an intake of $\geq 95\%$ of the prescribed medication were considered adherent; and those with a reported intake of $< 95\%$ were considered non-adherent [30]. Disease/treatment knowledge was measured using tools which has eight questions taken from the previous similar study [31]. The presence of adverse drug reaction was assessed by asking the patient whether he/she experienced any of them in the last months. Socio-demographic factors, psychosocial and medication-related characteristics were measured as explanatory variables. Data were collected by three trained BSc nurses and one supervisor for a duration of one month.
Data quality control
The questionnaire was translated to the local language and then back to English by expertise to check for consistency. Five percent (5%) of the questionnaire was pre-tested at Gimbi general hospital and some modifications were made based on the results. The one-day training was given for data collectors. The supervisor was also trained on how to monitor the data collection process.

Data processing and analysis
The data were coded, checked, cleaned and entered into Epi data version 3.1 and exported to Statistical Package for Social Sciences (SPSS) version 20.0 for analysis. Frequencies, percentages, and other descriptive statistics were done as univariate analysis. Bivariable logistic regression was done to find an association between each independent variable and adherence to antiretroviral medication. All independent variables were entered into multivariable logistic regression for further analysis. Finally, multivariable logistic regression with backward elimination was used to find out the independent variables which best predict patient’s adherence to antiretroviral medication. All association and statistical significance were measured using an odds ratio at a 95% confidence interval with a p-value of less than 0.05.

Ethical consideration
This study was reviewed and approved by the Institutional Review Boards of Wollega University. The purpose of the study was explained to the medical director and staff of the hospital. Written informed consent was obtained from the study participants. The patients’ information was also kept confidential.

Results
Socio-demographic characteristics of participants
Out of the total of 311 study participants sampled, 305 have participated in the study making a response rate of 98.07%. From a total of 305 participants, 140 (45.9%) were male. One hundred six (34.8%) of the study participants lie in the age group between 29–38 years. The minimum age of the study participants was 18 years and the maximum age was 56 years, with a median of 31.00 years. Concerning marital status, 126 (41.3%) of the study participants were single. The majority of the study participants were Oromo 184 (60.3%) in Ethnicity. Concerning educational status, 123 (40.3%) were completed grades 9–12. Regarding monthly income, 81 (26.6%) gets a monthly income of 1501–2000 Ethiopian birr. (Table 1).

Clinical and behavioral characteristics of participants
The majority of the study participants, 212 (69.5%) had no co-morbidity of other chronic diseases. Two hundred-one (65.9%) had knowledge about HIV and its treatment. Two hundred seven (67.9%) had disclosed their HIV status to their family. One hundred forty (45.9%) had CD4 count between 200–500 cells. Regarding the stage of HIV, 116 (38.0%) were on stage II and 98 (32.1%) were on stage I. One hundred thirty-eight (45.2%) of the study participants had strong social support. More than half of the study participants, 180 (59.0%) don’t experienced social stigma. One hundred ninety-four (63.6%) of the study participants had no history of current substance use. Concerning the disease duration, 115 (37.7%) had a duration of 6–10 years. The majority of the study participants, 191 (62.6%) had no adverse drug reaction. (Table 2).
Level of adherence to medication among the study participants

The adherence rate was calculated by dividing the number of pills the patient actually taken by the number of tablets patients should have taken multiplied by 100. About 3 (1.0%) of the study participants have adherence rate of < 70%, 7 (2.3%) have adherence rate of 70–79.99%, 12 (3.9%) have adherence rate of 80–89.99%, 60 (19.7%) have an adherence rate of 90–94.99%
and 223 (73.1%) have an adherence rate of ≥ 95%. Then, based on WHO guidelines, patients who reported an intake of ≥ 95% of the prescribed medication were considered adherent and those with a reported intake of < 95% were considered as non-adherent [30]. Accordingly, out of the total of 305 study participants, 223 (73.1%) were adherent to their medication (95%
CI = 68.2, 78.0) and 82 (26.9%) were not adherent to their medication (95% CI = 22.0, 31.8). (Fig 1).

**Bivariable logistic regression analysis**

In bivariable analysis, socio-demographic characteristics such as age, marital status, income, and a living companion were associated with adherence to the antiretroviral medication. On the other hand, clinical variables such as the side effects of ARV medication, knowledge about HIV and its treatment and comorbidity of other chronic illness were associated with adherence. Behavioral related variables such as family/social support, history of substance use, disclosure of HIV status to family and perceived social stigma were also associated with adherence to the antiretroviral medication at P-value less than 0.05. (Table 3).

**Multivariable logistic regression analysis**

In the final model of logistic regression, variables such as adverse drug reaction, social/family support, comorbidity of other chronic diseases, knowledge about HIV and its treatment and disclosure of HIV status to the family were associated with adherence to the antiretroviral medication at P value less than 0.05. Study participants who had strong family/social support were more likely to adhere to their medication than those who had poor family/social support (AOR = 6.21, 95% CI: 1.39, 27.62). Study participants who had knowledge about HIV and its treatment were more likely to adhere to their medication than those who had no knowledge about HIV and its treatments (AOR = 8.24, 95% CI: 3.10, 21.92). Respondents who didn’t develop adverse drug reactions were more likely to adhere to their medication than those who developed adverse drug reactions (AOR = 5.33, 95% CI: 1.95, 14.57). Study participants who had no other comorbid chronic diseases were more likely to adhere to their medication than those who had other comorbid chronic illness (AOR = 5.72, 95% CI: 1.91, 17.16). Study
Table 3. Bivariable logistic regression analysis of factors associated with adherence among HIV/AIDS patients at Nekemte referral hospital, West Ethiopia, 2019 (n = 305).

| Variables             | Adherence |                               | COR (95%) CI | P value |
|-----------------------|-----------|-------------------------------|--------------|---------|
|                       | Adherent (%) | Not adherent (%)             |              |         |
| **Sex**               |            |                               |              |         |
| Male                  | 97 (69.3%)  | 43 (30.7%)                   | 1            |         |
| Female                | 126 (76.4%) | 39 (23.6%)                  | 1.43 (0.86, 2.38) | 0.16    |
| **Age (years)**       |            |                               |              |         |
| 18–28                 | 69 (66.3%)  | 35 (33.7%)                   | 2.36 (1.04, 5.36) | 0.04*   |
| 29–38                 | 78 (73.6%)  | 28 (26.4%)                   | 1.57 (0.73, 3.40) | 0.24    |
| 39–48                 | 36 (78.3%)  | 10 (21.7%)                   | 1.08 (0.42, 2.73) | 0.86    |
| >48                   | 40 (81.6%)  | 9 (18.4%)                    | 1            |         |
| **Marital status**    |            |                               |              |         |
| Married               | 81 (80.2%)  | 20 (19.8%)                   | 1            |         |
| Single                | 92 (73.0%)  | 34 (27.0%)                   | 0.66 (0.35, 1.25) | 0.20    |
| Divorced              | 26 (65.0%)  | 14 (35.0%)                   | 0.45 (0.20, 1.03) | 0.06    |
| Widowed               | 24 (63.2%)  | 14 (36.8%)                   | 0.42 (0.18, 0.96) | 0.04*   |
| **Ethnicity**         |            |                               |              |         |
| Oromo                 | 134 (72.8%) | 50 (27.2%)                   | 1            |         |
| Amhara                | 61 (75.3%)  | 20 (24.7%)                   | 1.13 (0.62, 2.07) | 0.67    |
| Tigre                 | 13 (72.2%)  | 5 (27.8%)                    | 0.97 (0.32, 2.86) | 0.95    |
| Gurage                | 9 (75.0%)   | 3 (25.0%)                    | 1.11 (0.29, 4.30) | 0.87    |
| Others                | 6 (60.0%)   | 4 (40.0%)                    | 0.56 (0.15, 2.06) | 0.38    |
| **Educational status**|            |                               |              |         |
| No formal education   | 11 (55.0%)  | 9 (45.0%)                    | 0.40 (0.13, 1.20) | 0.10    |
| Primary school (1–8)  | 73 (66.4%)  | 37 (33.6%)                   | 0.65 (0.31, 1.38) | 0.26    |
| Secondary school (9–12)| 100 (81.3%)| 23 (18.7%)                   | 1.44 (0.66, 3.14) | 0.34    |
| College and above     | 39 (75.0%)  | 13 (25.0%)                   | 1            |         |
| **Residence**         |            |                               |              |         |
| Urban                 | 62 (68.9%)  | 28 (31.1%)                   | 1            |         |
| Rural                 | 161 (74.9%) | 54 (25.1%)                   | 1.34 (0.78, 2.31) | 0.28    |
| **Occupation**        |            |                               |              |         |
| Government employee   | 28 (80.0%)  | 7 (20.0%)                    | 1            |         |
| Private employee      | 72 (75.0%)  | 24 (25.0%)                   | 0.75 (0.29, 1.93) | 0.55    |
| Farmer                | 56 (67.5%)  | 27 (32.5%)                   | 0.51 (0.20, 1.33) | 0.17    |
| Merchant              | 58 (71.6%)  | 23 (28.4%)                   | 0.63 (0.24, 1.64) | 0.34    |
| Others                | 9 (90.0%)   | 1 (10.0%)                    | 2.25 (0.24, 20.83) | 0.47    |
| **Income**            |            |                               |              |         |
| <500 EB               | 35 (56.5%)  | 27 (43.5%)                   | 0.23 (0.07, 0.67) | 0.008*  |
| 500–1000 EB           | 41 (73.2%)  | 15 (26.8%)                   | 0.48 (0.15, 1.49) | 0.21    |
| 1001–1500 EB          | 51 (69.9%)  | 22 (30.1%)                   | 0.41 (0.14, 1.21) | 0.10    |
| 1501–2000 EB          | 68 (84.0%)  | 13 (16.0%)                   | 0.93 (0.30, 2.86) | 0.90    |
| >2000 EB              | 28 (84.8%)  | 5 (15.2%)                    | 1            |         |
| **Number of pills taken in a day** | | | | |
| 2 tablets             | 114 (75.5%) | 37 (24.5%)                   | 1            |         |
| 3 tablets             | 52 (72.2%)  | 20 (27.8%)                   | 0.84 (0.44, 1.59) | 0.60    |
| 4 tablets             | 43 (69.4%)  | 19 (30.6%)                   | 0.73 (0.38, 1.41) | 0.35    |
| >4 tablets            | 14 (70.0%)  | 6 (30.0%)                    | 0.75 (0.27, 2.11) | 0.59    |
| **Living companion**  |            |                               |              |         |
| Yes                   | 178 (88.1%) | 24 (11.9%)                   | 9.55 (5.36, 17.0) | 0.000*  |

(Continued)
Table 3. (Continued)

| Variables                                | Adherence |                  |                  |                  |                  |
|------------------------------------------|-----------|------------------|------------------|------------------|------------------|
|                                          | Adherent (%) | Not adherent (%) | COR (95%) CI     | P value          |
| No                                       | 45 (43.7%) | 58 (56.3%)       | 1                |                  |
| CD4 cell                                 |           |                  |                  |                  |
| <200                                     | 31 (73.8%) | 11 (26.2%)       | 1.40 (0.35, 5.62) | 0.62             |
| 200–500                                  | 100 (71.4%) | 40 (28.6%)    | 1.25 (0.35, 4.38) | 0.72             |
| 501–800                                  | 84 (75.7%) | 27 (24.3%)       | 1.55 (0.43, 5.57) | 0.49             |
| >800                                     | 8 (66.7%)  | 4 (33.3%)        |                  |                  |
| HIV stage                                |           |                  |                  |                  |
| Stage I                                  | 73 (74.5%) | 25 (25.5%)       | 1                |                  |
| Stage II                                 | 88 (75.9%) | 28 (24.1%)       | 1.07 (0.57, 2.00) | 0.81             |
| Stage III                                | 31 (64.6%) | 17 (35.4%)       | 0.62 (0.29, 1.31) | 0.21             |
| Stage IV                                 | 31 (72.1%) | 12 (27.9%)       | 0.88 (0.39, 1.98) | 0.76             |
| Side effect of ARV drugs                 |           |                  |                  |                  |
| Yes                                      | 44 (38.6%) | 70 (61.4%)       | 1                |                  |
| No                                       | 179 (93.7%) | 12 (6.3%)       | 23.7 (11.83, 47.57) | 0.000*          |
| Family/social support                    |           |                  |                  |                  |
| Strong                                   | 134 (97.1%) | 4 (2.9%)        | 20.79 (6.54, 66.02) | 0.000*          |
| Moderate                                 | 60 (50.0%) | 60 (50.0%)       | 0.62 (0.31, 1.23) | 0.17             |
| Poor                                     | 29 (61.7%) | 18 (38.3%)       | 1                |                  |
| Perceived stigma                         |           |                  |                  |                  |
| Yes                                      | 59 (47.2%) | 66 (52.8%)       | 1                |                  |
| No                                       | 164 (91.1%) | 16 (8.9%)       | 11.46 (6.15, 21.35) | 0.000*          |
| Substance use                            |           |                  |                  |                  |
| Yes                                      | 46 (41.4%) | 65 (58.6%)       | 1                |                  |
| No                                       | 177 (91.2%) | 17 (8.8%)       | 14.71 (7.87, 27.47) | 0.000*          |
| Disease duration                         |           |                  |                  |                  |
| <1 year                                  | 35 (74.5%) | 12 (25.5%)       | 0.87 (0.32, 2.36) | 0.79             |
| 1–5 years                                | 76 (73.1%) | 28 (26.9%)       | 0.81 (0.34, 1.98) | 0.64             |
| 6–10 years                               | 82 (71.3%) | 33 (28.7%)       | 0.74 (0.31, 1.74) | 0.49             |
| >10 years                                | 30 (76.9%) | 9 (23.1%)        | 1                |                  |
| Treatment duration                       |           |                  |                  |                  |
| <1 year                                  | 38 (79.2%) | 10 (20.8%)       | 1                |                  |
| 1–5 years                                | 85 (73.3%) | 31 (26.7%)       | 0.72 (0.32, 1.62) | 0.42             |
| 6–10 years                               | 78 (69.6%) | 34 (30.4%)       | 0.60 (0.27, 1.35) | 0.21             |
| >10 years                                | 22 (75.9%) | 7 (24.1%)        | 0.82 (0.27, 2.48) | 0.73             |
| Knowledge about HIV and its treatment    |           |                  |                  |                  |
| Knowledgeable                            | 181 (90.0%) | 20 (10.0%)      | 13.36 (7.29, 24.47) | 0.000*          |
| Not knowledgeable                        | 42 (40.4%) | 62 (59.6%)       | 1                |                  |
| Waiting time                             |           |                  |                  |                  |
| <30 minutes                              | 140 (75.3%) | 46 (24.7%)      | 1.32 (0.79, 2.20) | 0.28             |
| >/= 30 minutes                           | 83 (69.7%) | 36 (30.3%)       | 1                |                  |
| comorbidit y of other chronic illness    |           |                  |                  |                  |
| Yes                                      | 35 (37.6%) | 58 (62.4%)       | 1                |                  |
| No                                       | 188 (88.7%) | 24 (11.3%)      | 12.98 (7.14, 23.58) | 0.000*          |
| Family disclosure status                 |           |                  |                  |                  |
| Yes                                      | 184 (88.9%) | 23 (11.1%)      | 12.10 (6.68, 21.89) | 0.000*          |
| No                                       | 39 (39.8%) | 59 (60.2%)       | 1                |                  |

* shows significant at P-value <0.05

COR: Crude Odd Ratio, CI: Confidence Interval

https://doi.org/10.1371/journal.pone.0232703.t003
participants who disclosed their HIV status to their family were more likely to adhere to their medication than those who don’t disclose their HIV status to their family (AOR = 5.08, 95% CI: 2.09, 12.34). (Table 4).

**Discussion**

This study examined the level of adherence to ART and associated factors among HIV/AIDS patients in the Nekemte referral hospital, West Ethiopia in March 2019. The overall level of adherence to medication among peoples living with HIV/AIDS in this study is 73.1%. This level of adherence is slightly consistent with the study done in Southern Ethiopia (68.0%) [32], Northern Tanzania (71.0%) [19] and South Africa (69.0%) [33]. However, it is lower than a study done in China (85.5%) [17], Eastern Ethiopia (85.0%) [34], North-West Ethiopia (88.2%) [21], Nepal (87.4%) [35], Myanmar (84.0%) [18], Togo (78.4%) [36] and Indonesia (84.16%) [37]. On the other hand, the levels of adherence to ARV medication in this study is higher than the study done in Ghana (62.2%) [20] and Nyamagana-Mwanza (54.9%) [31]. The difference might be due to variation in sample size, study setting, study design, and study participant’s variation. The level of adherence in this study is lower than the world health organization recommendation level [30]. Our current finding showed that adherence to ART is low and emphasis should be placed on counseling the patient on the importance of strict adherence to the medication.

In this study, factors such as social/family support, adverse drug reaction, Knowledge about HIV and its treatment, family disclosure status and comorbidity of other chronic diseases were significantly associated with adherence to ARV medication. Respondents who had strong family/social support were found to be more adherent to their medication than those who have poor family/social support. Support from family and friends has immediate and long-term
positive influences on their adherence. This finding is consistent with the study done in Indonesia [37], Ghana [20], Eastern Ethiopia [34] and Sub-Saharan Africa [38]. However, the study done in China [17], Southern Ethiopia [32], South Africa [33], Nepal [35], Myanmar [18], Togo [36] and North West Ethiopia [21] didn’t show a significant association between family/social support and adherence to antiretroviral medication. The presence of support groups is a facilitator for adherence to the medication. It also provides a comfortable environment for sharing experiences and encouragement. Social support boosts the patient’s self-esteem and makes easy for the patient to adhere to ART. In contrast, if a patient does not have the support, it becomes difficult for the patient because the situation brings them to be hopeless and be the potential to refuse the treatment.

Respondents who didn’t develop adverse drug reactions were more adherent to their medication than those who developed an adverse drug reaction. Adherence to antiretroviral therapy was negatively affected by medication side effects. This might be due to the fact that study participants might skip their medication to avoid drug side effects. This finding is consistent with a study done in Ghana [20], Sub-Saharan Africa [38], Nepal [35], South Africa [33] and Cameroon [39]. However, this finding is not supported by the study done in China [17], Eastern Ethiopia [34], Togo [36], Myanmar [18] and North West Ethiopia [21].

The finding of this study also showed that study participants who had knowledge about HIV and its treatment were more adherent to their medication than those who had no knowledge about HIV and its treatment. This is due to the fact that knowledge of HIV and its treatment might increase their awareness and access to HIV therapy. This finding is consistent with the study done in North West Ethiopia [21], but not supported by many other studies [32, 17, 34, 20, 33, 35 and 18].

In this study, study participants who disclosed their HIV status to their families were more adherent to their medication than who didn’t disclose their HIV status to their families. This is similar to a study done in China [17], Tanzania [31], Eastern Ethiopia [34], North West Ethiopia [21], South Africa [33], Myanmar [18] and Togo [36]. When there is no self-disclosure about HIV status, the persons may fear to take their treatments and miss the medication. Disclosing HIV status to families enables PLWH to seek information, express feelings and access support groups. Participants who did not disclose their HIV status put more pressure on themselves and might skip their medication. On the other hand, non-disclosure might impede the participants from obtaining social support.

Respondents who had no comorbidity of other chronic illnesses were more adherent to their medication than those who had comorbidity of other chronic illnesses. The possible reason might be that when the patients had co-morbidities, they might have a pill burden. When the number of pill increases, the patient might experience more adverse effects from the medications which potentially lead them to skip their treatment. This finding is supported by the study done in China [17], Cameroon [39], Eastern Ethiopia [34], Southern Ethiopia [32], and North West Ethiopia [21]. However, this finding is not supported by the study done in Ghana [20] and Northern Tanzania [19]. Unlike other studies done in different parts of the world, age, monthly income, marital status, waiting time, the number of pills and substance use didn’t show significant association with adherence in this study.

Limitation of the study

Since the study was conducted at a single hospital, the results cannot be generalized to people living with HIV/AIDS in Ethiopia. Causality cannot be confirmed since the study design is cross-sectional.
Conclusion

In this study, the level of adherence to antiretroviral therapy was found low compared to the WHO recommendation. Having knowledge about HIV and its treatment, having strong family/social support, absence of adverse drug reactions, no comorbidity of other chronic diseases and disclosing HIV status to the family were significantly associated with an increased likelihood of adherence to antiretroviral medication. The clinician should focus on adverse drug reactions, early detect and treat co-morbidities, improve knowledge through health education, and encourage HIV/AIDS patients to disclose their HIV status to their families to improve adherence to antiretroviral medication.

Supporting information

S1 Questionnaire.
(DOCX)

S1 Dataset.
(SAV)

Acknowledgments

We would like to acknowledge Nekemte referral hospital medical director and staffs for their cooperation. We are also grateful to the study participants who voluntarily agreed to be interviewed and participated in the study.

Author Contributions

Conceptualization: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Data curation: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Formal analysis: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Investigation: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Methodology: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Project administration: Muktar Abadiga, Tahir Hasen, Getu Mosisa.

Resources: Muktar Abadiga, Tahir Hasen, Eba Abdisa.

Software: Muktar Abadiga, Getu Mosisa.

Supervision: Muktar Abadiga, Eba Abdisa.

Validation: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Visualization: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Writing – original draft: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

Writing – review & editing: Muktar Abadiga, Tahir Hasen, Getu Mosisa, Eba Abdisa.

References

1. WHO. HIV/AIDS and mental health. Geneva: Switzerland; 2008.
2. WHO. HIV/AIDS (Internet). WHO. http://www.who.int/gho/hiv/en/. Accessed 23 December 2019.
3. U. Nation, United Nations Political Declaration on Ending AIDS: 2020 Global Prevention Targets and Commitments, 2016.
4. Granich R, Gupta S, Williams B (2018) 90-90-90, Epidemic Control and Ending AIDS: Global Situation and Recommendations. Int J Virol AIDS 5:043. doi.org/10.23937/2469-567X-1510043

5. 90–90–90—An ambitious treatment target to help end the AIDS epidemic | UNAIDS [Internet]. (Accessed 10 April 2020). http://www.unaids.org/en/resources/documents/2014/90-90-90

6. Hill A, Pozniak A (2015) HIV treatment cascades: How can all countries reach the UNAIDS 90-90-90 target? AIDS 29: 2523–2525. https://doi.org/10.1097/QAD.0000000000000604 PMID: 26558548

7. World Health Organization. Adherence to long-term therapies: evidence for action. WHO. 2003; P3

8. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002; 34:1115–21. https://doi.org/10.1086/339074 PMID: 11915001

9. UNAIDS. GLOBAL AIDS UPDATE. 2016. http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.

10. ART failure and strategies for switching ART regimens, Report of the WHO expert consultation Copenhagen, 7 December 2007.

11. Jean B, Nachega MH, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and Virologic outcomes. Ann Intern Med. 2007; 146:564–73. https://doi.org/10.7326/0003-4819-146-6-200704170-00007 PMID: 17438315

12. Jean B, Nachega MH, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, Virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009; 51(1):65–71. https://doi.org/10.1097/QAI.0b013e1819f97072e PMID: 19262780

13. David L, Paterson M, BS FRACP, Swindells S, Mohr J, MS W, Brester M, R N, Emanuel N, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21–30. https://doi.org/10.7326/0003-4819-133-1-200007040-00004 PMID: 10677736

14. Sharon Mannheimer GF, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus–infected persons in clinical trials. Clin Infect Dis. 2002; 34(8):1115–21. https://doi.org/10.1086/339074 PMID: 11915001

15. Howard AAA, Julia H, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. International AIDS society. 2002; 16(16):2175–82.

16. Edward L. Machtinger DRB. Adherence to HIV antiretroviral therapy. University of California san Francisco: HIV InSite Knowledge Base chapter; 2006.

17. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC Public Health (2018) 18:825 https://doi.org/10.1186/s12889-018-5731-z PMID: 29973167

18. Aye WL, Puckpinyo A, Peltzer K. Non-adherence to anti-retroviral therapy among HIV infected adults in Mon State of Myanmar. BMC Public Health (2017) 17:391 https://doi.org/10.1186/s12889-017-4309-5 PMID: 28476150

19. Semvua SK, Orrell C, Mmbaga BT, Semvua HH, Bartlett JA, Bouille AA (2017) Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. PLoS ONE 12(12): e0189460. https://doi.org/10.1371/journal.pone.0189460 PMID: 29252984

20. Obiri korang C, Selegh PK, Abledu JK, Folie CO. Predictors of Adherence to Antiretroviral Therapy among HIV/AIDS Patients in the Upper West Region of Ghana. ISRNAIDS Volume 2013, Article ID 873939,7pages http://dx.doi.org/10.1155/2013/873939

21. Molia AA, Gelagay AA, Mekonnen HS, Teshome DF. Adherence to antiretroviral therapy and associated factors among HIV positive adults attending care and treatment in University of Gondar Referral Hospital, Northwest Ethiopia. BMC Infectious Diseases (2018) 18:226 https://doi.org/10.1186/s12879-018-3176-8 PMID: 29879913

22. Li JZ, G SR H, Haiseya A, Bangsbergd DR, Kuritzkesa DR. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014; 28(2):181–6. https://doi.org/10.1097/QAD.0000000000000123 PMID: 24361679

23. ID JAGS, de Brito AM, da Silva CAL. Factors associated with non-adherence to antiretroviral therapy in adults with AIDS in the first six months of treatment in Salvador, Bahia state, Brazil. Cad Sa de Pública, Rio de Janeiro. 2015; 31(6):1–11.

24. Hogan D, Salomon J (2005) Prevention and treatment of HIV/AIDS in resource limited settings. Bulletin of WHOM 83:2.

25. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21–30. https://doi.org/10.7326/0003-4819-133-1-200007040-00004 PMID: 10877736
26. Sahay S, Reddy KS, Dhayarkar S. Optimizing adherence to antiretroviral therapy. Indian J Med Res. 2011; 134(6):835. https://doi.org/10.4103/0971-5916.92629 PMID: 22310817

27. Tefera G. Personal factors influencing patients ART adherence in Addis Ababa, Ethiopia. J Assoc Nurses AIDS Care. 2011; 24(6):530–8.

28. Kocalevent RD, Berg L, Beutel ME, Hinz A, Zenger M, Härtner M, et al. Social support in the general population: standardization of the Oslo social support scale (OSSS-3). BMC Psychology (2018) 6:31 https://doi.org/10.1186/s40359-018-0249-9 PMID: 30016997

29. Reinius M, Wettergren L, Wiklander M, Svedhem V, Ekström A, Eriksson LE. Development of a 12-item short version of the HIV stigma scale. Health and Quality of Life Outcomes (2017) 15:115 https://doi.org/10.1186/s12955-017-0691-z PMID: 28558805

30. World Health Organization, Adherence to Long-Term Therapies Evidence for Action World Health Organization; 2013; XII: 92–106.

31. Kahema SE, Mgabo MR, Emidi B, Sigalla GN, Kajeguka DC (2018) Factors Influencing Adherence to Antiretroviral Therapy among HIV Infected Patients in Nyamagana-Mwanza, Northern Tanzania: A Cross Sectional Study. Int Arch Med Microbiol 1:002.

32. Koyra HC (2018) Adherence to Antiretroviral Therapy among Adult Persons Living with HIV/ AIDS in Southern Ethiopia. Int J Virol AIDS 5:038. doi:10.23937/2469-567X/1510038

33. Adeniyi OV, Ajayi AI, Goon DT, Owolabi EO, Eboh A, Lambert J. Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa. BMC Infectious Diseases (2018) 18:175 https://doi.org/10.1186/s12879-018-3087-8 PMID: 29653510

34. Letta S, Demissie A, Oljira L, Dessie Y. Factors associated with adherence to Antiretroviral Therapy (ART) among adult people living with HIV and accessing their clinical care, Eastern Ethiopia. BMC International Health and Human Rights (2015) 15:33 https://doi.org/10.1186/s12914-015-0071-x PMID: 26711659

35. Neupane S, Dhungana GP, Ghimire HC. Adherence to antiretroviral treatment and associated factors among people living with HIV and AIDS in CHITWAN, Nepal. BMC Public Health (2019) 19:720 https://doi.org/10.1186/s12889-019-7051-3 PMID: 31182074

36. Yaya I, Londoh DE, Saka B, Patchali PM, Wasspa P, Aboubakari AS, et al. Predictors of adherence to antiretroviral therapy among people living with HIV and AIDS at the regional hospital of Sokode, Togo. BMC Public Health 2014, 14:1308 http://www.biomedcentral.com/1471-2458/14/1308 PMID: 25526773

37. Suryana K., Suharsono H. and Antara J. Factors Associated with Adherence to Anti-Retroviral Therapy Among People Living with HIV/AIDS at Wangaya Hospital in Denpasar, Bali, Indonesia: A Cross-Sectional Study, HIV/AIDS—Research and Palliative Care 2019: 11

38. Ammon N., Mason S., Kerkery J.M. Factors impacting antiretroviral therapy adherence among human immune deficiency -positive adolescents in Sub-Saharan Africa: a systematic review, Public health 157 (2018) 20–31. https://doi.org/10.1016/j.puhe.2017.12.010 PMID: 29501984

39. Fonsah JY, Njamnshi AK, Kouanfack C, Qui F, Njamnshi DM, Tagny CT, et al. (2017) Adherence to Antiretroviral Therapy (ART) in Yaoundé -Cameroon: Association with Opportunistic Infections, Depression, ART Regimen and Side Effects. PLoS ONE 12(1): e0170893. https://doi.org/10.1371/journal.pone.0170893 PMID: 28141867